Trial Profile
A prospective open-label, single-arm, multicenter, Phase 2 study of amrubicin plus durvalumab in Japanese pts with relapsed SCLC
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 28 Jun 2023
Price :
$35
*
At a glance
- Drugs Amrubicin (Primary) ; Durvalumab (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- Acronyms Aphrodite
- 28 Jun 2023 New trial record
- 06 Jun 2023 Trial design, presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 06 Jun 2023 Enrollment will be completed by March 2025, as per trial design, presented at the 59th Annual Meeting of the American Society of Clinical Oncology